Picard Medical to Begin Rollout of FDA-Cleared Accessory for its SynCardia Total Artificial Heart

StockNews.AI • 3 days

BullishShort TermCorporate DevelopmentsDOV ABMD MDT

High Materiality8/10

Information

TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard”...

Corporate Developments

The announcement focuses on product enhancements that directly relate to patient care, crucial for a medical device company. Improved safety features can lead to increased market share and higher investor interest.

FAQ

Why Bullish?

The introduction of an enhanced product feature can drive sales and improve market confidence. Historically, product improvements lead to stock price upticks in medical device companies.

How important is it?

The announcement focuses on product enhancements that directly relate to patient care, crucial for a medical device company. Improved safety features can lead to increased market share and higher investor interest.

Why Short Term?

The scheduled rollout on January 15, 2026, will likely produce immediate market reactions. As recent product upgrades often stimulate sales in the short term, investor sentiment may rise swiftly.

Related Companies

DOV ABMD MDT

Picard Medical Advances Patient Comfort with New Accessory for Total Artificial Heart

TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) has announced its plans to integrate a new FDA-cleared accessory into its renowned SynCardia Total Artificial Heart (STAH) system. This initiative aims to enhance patient comfort while reinforcing the safety and reliability of the device.

Introduction of CPC1 Connector Covers

The new component, known as CPC1 “Connector Covers,” will provide additional protection over the metal release buttons located on the STAH's CPC connectors. These connectors play a critical role by linking the SynCardia Drivers to the two pneumatic drive cannulas functioning in the STAH ventricles. The incorporation of these covers is set to begin on January 15, 2026, as part of the standard clinical practice for patients in the U.S.

Commitment to Patient Safety and Quality of Life

“Patient safety and quality of life are central to everything we do,” stated Steve Langford, Senior Clinical Specialist at SynCardia Systems. He emphasized that this enhancement is part of the company’s ongoing commitment to implementing practical improvements that support both patient and clinician confidence.

Training and Implementation

In preparation for the rollout, all SynCardia sales and clinical staff have completed the necessary training. SynCardia will collaborate directly with hospital and clinical teams to provide comprehensive training materials, implementation guidance, and ongoing support for existing patients.

About Picard Medical

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, based in Tucson, Arizona. The company is a leader in the field of artificial heart technology, offering the only commercially available total artificial heart system for patients suffering from end-stage heart failure. With over 2,100 implants conducted in hospitals across 27 countries, the SynCardia Total Artificial Heart remains the most widely utilized and rigorously studied artificial heart globally.

For more information, please visit www.syncardia.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such statements are not historical facts and could lead to actual results that differ significantly from expectations. The company disclaims any obligation to update or revise its forward-looking statements following changes in expectations or circumstances.

Contact Information

Investors: Eric Ribner, Managing Director, LifeSci Advisors LLC, eric@lifesciadvisors.com
Company Inquiries: Picard Medical, Inc./SynCardia Systems, LLC, IR@picardmedical.com
Media: Brittany Lanza, blanza@syncardia.com